Sunshine Biopharma (SBFM) Asset Writedowns and Impairment (2025)

Sunshine Biopharma (SBFM) reported Asset Writedowns and Impairment of $131788.0 for Q4 2025, down 76.24% quarter-over-quarter from $554650.0 in Q3 2025.

Sunshine Biopharma (SBFM) Asset Writedowns and Impairment (2025) Analysis & Trends

Sunshine Biopharma has reported Asset Writedowns and Impairment for 1 years, with the latest figure at $131788.0 in Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $131788.0; the trailing twelve-month figure through Dec 2025 stood at $1.7 million (changed N/A YoY), and the FY2025 full-year result was $1.7 million, changed N/A from the prior year.
  • Asset Writedowns and Impairment for Q4 2025 stood at $131788.0, down from $554650.0 in the prior quarter.
  • The five-year high for Asset Writedowns and Impairment was $1.1 million in Q2 2025, with the low at $131788.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Sunshine Biopharma 10.94 Mn 4.03 Mn 2.18 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 131,788.00
Dec 31, 2025 131,788.00
Sep 30, 2025 554,650.00
Sep 30, 2025 554,650.00
Jun 30, 2025 1.06 Mn
Jun 30, 2025 1.06 Mn